Covered recipient · General Payments record
DWIGHT DENMAN BLAKE
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$1,138.93
6 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Travel and Lodging | $615.32 | 3 |
| Food and Beverage | $523.61 | 3 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Eli Lilly and Company | $896.67 | 4 |
| Metuchen Pharmaceuticals | $125.00 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $117.26 | 1 |
Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
DWIGHT DENMAN BLAKE
NPI 1811938814 · CMS profile ID 173473
Allopathic & Osteopathic Physicians / Internal Medicine
UNION CITY, GA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1811938814?year=2019&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- DWIGHT DENMAN BLAKE, NPI 1811938814, CMS profile ID 173473. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1811938814?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). DWIGHT DENMAN BLAKE, NPI 1811938814, CMS profile ID 173473. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1811938814?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- DWIGHT DENMAN BLAKE, NPI 1811938814, CMS profile ID 173473, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1811938814?year=2019&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
6 matching records · $1,138.93 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–6 of 6.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $117.26 | 09/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700035649 | CMS |
| Metuchen Pharmaceuticals | $125.00 | 08/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 679321141 | CMS |
| Eli Lilly and Company | $281.35 | 02/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657785989 | CMS |
| Eli Lilly and Company | $182.85 | 02/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657785991 | CMS |
| Eli Lilly and Company | $85.01 | 02/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657803229 | CMS |
| Eli Lilly and Company | $347.46 | 02/21/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657785987 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $3,386,564.75 | 80 |
| PY2024 | Recipient | $57,732.20 | 4 |
| PY2024 | Principal investigator | $2,455,115.26 | 49 |
| PY2023 | Recipient | $2,277.99 | 4 |
| PY2023 | Principal investigator | $2,791,306.83 | 51 |
| PY2022 | Recipient | $92,276.00 | 3 |
| PY2022 | Principal investigator | $3,022,384.19 | 43 |
| PY2021 | Recipient | $6,646.99 | 2 |
| PY2021 | Principal investigator | $1,337,039.14 | 22 |
| PY2020 | Recipient | $1,658.45 | 3 |
| PY2020 | Principal investigator | $145,341.90 | 6 |
| PY2019 | Recipient | $24,425.96 | 3 |
| PY2019 | Principal investigator | $177,128.41 | 4 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
53 records in PY2024
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $927.00 | 12/31/2024 | Non-covered Recipient Entity SP RESEARCH PLLC | M21-572 Ph3 Ped FC Trial 2-5 (LIN-MD-68) (3051-303-001) | No dispute reported | 06/30/2026 | 1100766421 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $22,862.79 | 12/31/2024 | Non-covered Recipient Entity Rophe Adult and Pediatric Medicine,SKYCRNG | A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression | No dispute reported | 06/30/2026 | 1136419605 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $5,185.28 | 12/31/2024 | Non-covered Recipient Entity Rophe Adult and Pediatric Medicine,SKYCRNG | A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression | No dispute reported | 06/30/2026 | 1136419610 |
| Principal investigator 1 | PFIZER INC. | $19,785.00 | 12/17/2024 | Non-covered Recipient Entity SKY Clinical Research Network Group | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1130945658 |
| Principal investigator 1 | Chiesi USA, Inc. | $2,500.00 | 12/06/2024 | Non-covered Recipient Entity SKY CLINICAL RESEARCH NETWORK GROUP | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) | No dispute reported | 06/30/2026 | 1148225590 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $19,050.00 | 12/04/2024 | Non-covered Recipient Entity Rophe Adult and Pediatric Medicine,SKYCRNG | A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression | No dispute reported | 06/30/2026 | 1136419601 |
| Principal investigator 1 | PFIZER INC. | $2,257.20 | 11/20/2024 | Non-covered Recipient Entity Rophe Adult and Pediatric MedicineSKYCRNG | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1130916321 |
| Principal investigator 1 | PFIZER INC. | $853.20 | 11/20/2024 | Non-covered Recipient Entity Rophe Adult and Pediatric MedicineSKYCRNG | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1130917783 |
| Principal investigator 1 | PFIZER INC. | $156.00 | 11/20/2024 | Non-covered Recipient Entity ROPHE ADULT PED MEDSKYCRNG | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1130945652 |
| Principal investigator 1 | PFIZER INC. | $139.95 | 11/20/2024 | Non-covered Recipient Entity ROPHE ADULT PED MEDSKYCRNG | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1130945753 |
| Principal investigator 1 | Eli Lilly and Company | $285.16 | 11/18/2024 | Non-covered Recipient Entity SKY CLINICAL RESEARCH NETWORK GROUP | A STUDY OF ORFORGLIPRON FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (ATTAIN-MAINTAIN) | No dispute reported | 06/30/2026 | 1137367057 |
| Principal investigator 1 | Chiesi USA, Inc. | $1,125.00 | 11/13/2024 | Non-covered Recipient Entity SKY CLINICAL RESEARCH NETWORK GROUP | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) | No dispute reported | 06/30/2026 | 1148224888 |
| Principal investigator 1 | Eli Lilly and Company | $267,186.00 | 10/29/2024 | Non-covered Recipient Entity SKY CLINICAL RESEARCH NETWORK GROUP | A STUDY OF ORFORGLIPRON FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (ATTAIN-MAINTAIN) | No dispute reported | 06/30/2026 | 1137366875 |
| Principal investigator 1 | Chiesi USA, Inc. | $1,125.00 | 10/23/2024 | Non-covered Recipient Entity SKY CLINICAL RESEARCH NETWORK GROUP | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) | No dispute reported | 06/30/2026 | 1148224280 |
| Recipient | Eli Lilly and Company | $2,869.00 | 10/15/2024 | Covered Recipient Physician | A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) | No dispute reported | 06/30/2026 | 1137347244 |
| Recipient | Eli Lilly and Company | $49,905.00 | 09/24/2024 | Covered Recipient Physician | A STUDY OF LY3298176 (TIRZEPATIDE) FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES | No dispute reported | 06/30/2026 | 1137346906 |
| Recipient | Eli Lilly and Company | $4,859.00 | 09/24/2024 | Covered Recipient Physician | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1137347242 |
| Principal investigator 1 | Chiesi USA, Inc. | $3,625.00 | 09/18/2024 | Non-covered Recipient Entity SKY CLINICAL RESEARCH NETWORK GROUP | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) | No dispute reported | 06/30/2026 | 1148223202 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $29,025.00 | 09/05/2024 | Non-covered Recipient Entity SKY CLINICAL RESEARCH NETWORK GROUP | A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1156049303 |
| Recipient | Eli Lilly and Company | $99.20 | 08/26/2024 | Covered Recipient Physician | A STUDY OF ORFORGLIPRON FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (ATTAIN-MAINTAIN) | No dispute reported | 06/30/2026 | 1137345750 |
| Principal investigator 1 | Chiesi USA, Inc. | $7,209.00 | 08/14/2024 | Non-covered Recipient Entity SKY CLINICAL RESEARCH NETWORK GROUP | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) | No dispute reported | 06/30/2026 | 1148222408 |
| Principal investigator 1 | Eli Lilly and Company | $505.00 | 08/08/2024 | Non-covered Recipient Entity SKY CLINICAL RESEARCH NETWORK GROUP | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1137367717 |
| Principal investigator 1 | ABBVIE INC. | $2,801.14 | 08/02/2024 | Non-covered Recipient Entity SKY CLINICAL RESEARCH NETWORK GROUP | A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation | No dispute reported | 06/30/2026 | 1100735002 |
| Principal investigator 1 | Chiesi USA, Inc. | $11,920.00 | 07/24/2024 | Non-covered Recipient Entity SKY CLINICAL RESEARCH NETWORK GROUP | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) | No dispute reported | 06/30/2026 | 1148221560 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $25,285.00 | 07/11/2024 | Non-covered Recipient Entity SKY CLINICAL RESEARCH NETWORK GROUP | A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1156048987 |
| Principal investigator 1 | ABBVIE INC. | $3,398.96 | 07/05/2024 | Non-covered Recipient Entity SKY CLINICAL RESEARCH NETWORK GROUP | A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation | No dispute reported | 06/30/2026 | 1100728172 |
| Principal investigator 1 | Chiesi USA, Inc. | $2,500.00 | 06/28/2024 | Non-covered Recipient Entity SKY CLINICAL RESEARCH NETWORK GROUP | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) | No dispute reported | 06/30/2026 | 1148221062 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $9,905.91 | 06/27/2024 | Non-covered Recipient Entity ROPHE ADULT AND PEDIATRIC MEDICINE | A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease | No dispute reported | 06/30/2026 | 1095482546 |
| Principal investigator 1 | ABBVIE INC. | $2,288.52 | 06/06/2024 | Non-covered Recipient Entity SKY CLINICAL RESEARCH NETWORK GROUP | A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation | No dispute reported | 06/30/2026 | 1100722556 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $379.13 | 05/30/2024 | Non-covered Recipient Entity SKY CLINICAL RESEARCH NETWORK GROUP | A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1156048761 |
| Principal investigator 1 | Chiesi USA, Inc. | $5,960.00 | 05/15/2024 | Non-covered Recipient Entity SKY CLINICAL RESEARCH NETWORK GROUP | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) | No dispute reported | 06/30/2026 | 1148219906 |
| Principal investigator 1 | ABBVIE INC. | $5,812.44 | 05/08/2024 | Non-covered Recipient Entity SKY CLINICAL RESEARCH NETWORK GROUP | A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation | No dispute reported | 06/30/2026 | 1100716498 |
| Principal investigator 1 | PFIZER INC. | $15,300.00 | 04/05/2024 | Non-covered Recipient Entity SKY Clinical Research Network Group | A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332 NIRMATRELVIRRITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE | No dispute reported | 06/30/2026 | 1131087866 |
| Principal investigator 1 | PFIZER INC. | $5,787.50 | 03/29/2024 | Non-covered Recipient Entity SKY Clinical Research Network Group | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 1131100420 |
| Principal investigator 1 | ABBVIE INC. | $1,098.82 | 03/07/2024 | Non-covered Recipient Entity SKY CLINICAL RESEARCH NETWORK GROUP | A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation | No dispute reported | 06/30/2026 | 1100707614 |
| Principal investigator 1 | Chiesi USA, Inc. | $10,000.00 | 02/21/2024 | Non-covered Recipient Entity SKY CLINICAL RESEARCH NETWORK GROUP | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) | No dispute reported | 06/30/2026 | 1148216196 |
| Principal investigator 1 | PFIZER INC. | $295.40 | 02/21/2024 | Non-covered Recipient Entity SKY Clinical Research Network Group | A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 | No dispute reported | 06/30/2026 | 1130992616 |
| Principal investigator 1 | Eli Lilly and Company | $10,248.00 | 02/13/2024 | Non-covered Recipient Entity SKY CLINICAL RESEARCH NETWORK GROUP | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1137367855 |
| Principal investigator 1 | Eli Lilly and Company | $101,139.00 | 02/06/2024 | Non-covered Recipient Entity SKY CLINICAL RESEARCH NETWORK GROUP | A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) | No dispute reported | 06/30/2026 | 1137367511 |
| Principal investigator 1 | ABBVIE INC. | $2,933.20 | 02/01/2024 | Non-covered Recipient Entity SKY CLINICAL RESEARCH NETWORK GROUP | A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation | No dispute reported | 06/30/2026 | 1100702192 |
| Principal investigator 1 | Eli Lilly and Company | $147.60 | 01/31/2024 | Non-covered Recipient Entity SKY CLINICAL RESEARCH NETWORK GROUP | A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN DEGLUDEC IN INSULIN NAIVE ADULTS WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1137367735 |
| Principal investigator 1 | Eli Lilly and Company | $16,474.00 | 01/30/2024 | Non-covered Recipient Entity SKY CLINICAL RESEARCH NETWORK GROUP | A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN DEGLUDEC IN INSULIN NAIVE ADULTS WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1137366365 |
| Principal investigator 1 | Eli Lilly and Company | $1,280.04 | 01/12/2024 | Non-covered Recipient Entity SKY CLINICAL RESEARCH NETWORK GROUP | A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) | No dispute reported | 06/30/2026 | 1137366853 |
| Principal investigator 1 | Eli Lilly and Company | $1,129.84 | 01/12/2024 | Non-covered Recipient Entity SKY CLINICAL RESEARCH NETWORK GROUP | A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) | No dispute reported | 06/30/2026 | 1137367413 |
| Principal investigator 1 | Eli Lilly and Company | $3,607.65 | 01/12/2024 | Non-covered Recipient Entity SKY CLINICAL RESEARCH NETWORK GROUP | A STUDY OF LY3298176 (TIRZEPATIDE) FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES | No dispute reported | 06/30/2026 | 1137367415 |
| Principal investigator 1 | Eli Lilly and Company | $1,557.09 | 01/12/2024 | Non-covered Recipient Entity SKY CLINICAL RESEARCH NETWORK GROUP | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | No dispute reported | 06/30/2026 | 1137367729 |
| Principal investigator 1 | Eli Lilly and Company | $1,309.56 | 01/10/2024 | Non-covered Recipient Entity SKY CLINICAL RESEARCH NETWORK GROUP | A PHASE 3B, RANDOMIZED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TIRZEPATIDE COMPARED TO SEMAGLUTIDE 2.4 MG IN ADULTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (SURMOUNT-5) | No dispute reported | 06/30/2026 | 1137366871 |
| Principal investigator 1 | Eli Lilly and Company | $118,530.00 | 01/08/2024 | Non-covered Recipient Entity SKY CLINICAL RESEARCH NETWORK GROUP | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1137367723 |
| Principal investigator 1 | ABBVIE INC. | $4,003.88 | 01/04/2024 | Non-covered Recipient Entity SKY CLINICAL RESEARCH NETWORK GROUP | A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation | No dispute reported | 06/30/2026 | 1100698871 |
| Principal investigator 1 | Eli Lilly and Company | $742,634.00 | 01/02/2024 | Non-covered Recipient Entity SKY CLINICAL RESEARCH NETWORK GROUP | A PHASE 3B, RANDOMIZED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TIRZEPATIDE COMPARED TO SEMAGLUTIDE 2.4 MG IN ADULTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (SURMOUNT-5) | No dispute reported | 06/30/2026 | 1137366845 |
| Principal investigator 1 | Eli Lilly and Company | $96,659.00 | 01/02/2024 | Non-covered Recipient Entity SKY CLINICAL RESEARCH NETWORK GROUP | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | No dispute reported | 06/30/2026 | 1137366847 |
| Principal investigator 1 | Eli Lilly and Company | $451,836.00 | 01/02/2024 | Non-covered Recipient Entity SKY CLINICAL RESEARCH NETWORK GROUP | A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) | No dispute reported | 06/30/2026 | 1137367061 |
| Principal investigator 1 | Eli Lilly and Company | $415,092.00 | 01/02/2024 | Non-covered Recipient Entity SKY CLINICAL RESEARCH NETWORK GROUP | A STUDY OF LY3298176 (TIRZEPATIDE) FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES | No dispute reported | 06/30/2026 | 1137367063 |